AAAAAA

   
Results: 1-8 |
Results: 8
KNOWLEDGE AND BELIEFS ABOUT BREAST-CANCER PREVENTION IN AN UNSELECTEDFEMALE ITALIAN POPULATION
Authors: BIAMONTE R ROBBIATI SF CAFFO O TATA F SEQUI I FILIPPELLI G ROVITO A LIGUORI V CONFORTI S PALAZZO S
Citation: R. Biamonte et al., KNOWLEDGE AND BELIEFS ABOUT BREAST-CANCER PREVENTION IN AN UNSELECTEDFEMALE ITALIAN POPULATION, European journal of cancer, 34, 1998, pp. 297-297
ASSESSMENT OF THE RESPONSE WITH COLOR-DOPPLER SONOGRAPHY (CDS) IN PATIENTS AFFECTED BY BREAST-CANCER (BC) IN NEOADJUVANT CHEMOTHERAPY (NCT)
Authors: FILIPPELLI G BIRMONTE R CONFORTI S CRISPINO G LIGUORI V POMILLO A ROVITO A PALAZZO S
Citation: G. Filippelli et al., ASSESSMENT OF THE RESPONSE WITH COLOR-DOPPLER SONOGRAPHY (CDS) IN PATIENTS AFFECTED BY BREAST-CANCER (BC) IN NEOADJUVANT CHEMOTHERAPY (NCT), European journal of cancer, 34, 1998, pp. 490-490
BEING PREJUDICED DOESNT HELP, PREVENTING DOES - AN HEALTH PROMOTION (HP) INTERVENTION
Authors: CONFORTI S BIAMONTE R BOSCO A CONFORTI R FILIPPELLI G LIGUORI V MASTROIANNI C ROVITO A SANTELLI F PALAZZO S
Citation: S. Conforti et al., BEING PREJUDICED DOESNT HELP, PREVENTING DOES - AN HEALTH PROMOTION (HP) INTERVENTION, European journal of cancer, 34, 1998, pp. 13-13
A RISK MODEL FOR OVARIAN-CARCINOMA PATIENTS USING C-125 - TIME TO NORMALIZATION RENDERS 2ND-LOOK LAPAROTOMY REDUNDANT
Authors: FRASCI G CONFORTI S ZULLO F MASTRANTONIO P COMELLA G COMELLA P PERSICO G IAFFAIOLI RV
Citation: G. Frasci et al., A RISK MODEL FOR OVARIAN-CARCINOMA PATIENTS USING C-125 - TIME TO NORMALIZATION RENDERS 2ND-LOOK LAPAROTOMY REDUNDANT, Cancer, 77(6), 1996, pp. 1122-1130
CARBOPLATIN (CBDCA) HEXAMETHYLMELAMINE (HMM) ORAL ETOPOSIDE (VP-16) FIRST-LINE TREATMENT OF OVARIAN-CANCER PATIENTS WITH BULKY DISEASE - A PHASE-II STUDY
Authors: FRASCI G COMELLA G COMELLA P CONFORTI S MASTRANTONIO P ZULLO F PERSICO G
Citation: G. Frasci et al., CARBOPLATIN (CBDCA) HEXAMETHYLMELAMINE (HMM) ORAL ETOPOSIDE (VP-16) FIRST-LINE TREATMENT OF OVARIAN-CANCER PATIENTS WITH BULKY DISEASE - A PHASE-II STUDY, Gynecologic oncology, 58(1), 1995, pp. 68-73
CARBOPLATIN AND ALPHA-2B INTERFERON INTRAPERITONEAL COMBINATION AS FIRST-LINE TREATMENT OF MINIMAL RESIDUAL OVARIAN-CANCER - A PILOT-STUDY
Authors: FRASCI G TORTORIELLO A FACCHINI G CONFORTI S PERSICO G MASTRANTONIO P CARDONE A IAFFAIOLI RV
Citation: G. Frasci et al., CARBOPLATIN AND ALPHA-2B INTERFERON INTRAPERITONEAL COMBINATION AS FIRST-LINE TREATMENT OF MINIMAL RESIDUAL OVARIAN-CANCER - A PILOT-STUDY, European journal of cancer, 30A(7), 1994, pp. 946-950
COMPUTERIZED-TOMOGRAPHY OF THE ABDOMEN AND PELVIS WITH PERITONEAL ADMINISTRATION OF SOLUBLE CONTRAST (IPC-CT) IN DETECTION OF RESIDUAL DISEASE FOR PATIENTS WITH OVARIAN-CANCER
Authors: FRASCI G CONTINO A IAFFAIOLI RV MASTRANTONIO P CONFORTI S PERSICO G
Citation: G. Frasci et al., COMPUTERIZED-TOMOGRAPHY OF THE ABDOMEN AND PELVIS WITH PERITONEAL ADMINISTRATION OF SOLUBLE CONTRAST (IPC-CT) IN DETECTION OF RESIDUAL DISEASE FOR PATIENTS WITH OVARIAN-CANCER, Gynecologic oncology, 52(2), 1994, pp. 154-160
INTRAPERITONEAL (IP) CISPLATIN-MITOXANTRONE-INTERFERON-ALPHA-2B IN OVARIAN-CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE
Authors: FRASCI G TORTORIELLO A FACCHINI G CONFORTI S CARDONE A PERSICO G MASTRANTONIO P IAFFAIOLI RV
Citation: G. Frasci et al., INTRAPERITONEAL (IP) CISPLATIN-MITOXANTRONE-INTERFERON-ALPHA-2B IN OVARIAN-CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE, Gynecologic oncology, 50(1), 1993, pp. 60-67
Risultati: 1-8 |